Viking Therapeutics stock closed at $34.34, up 11.44%, fueled by VK2735 Phase 2 success. The trial delivered 14.7% average weight reduction, challenging GLP-1 leaders like Ozempic. Acquisition speculation boosts investor interest.
Shares of Viking Therapeutics, a clinical-stage biotechnology firm, rallied significantly, closing at $34.34 with an 11.44% gain. Investors showed renewed enthusiasm from strong clinical trial data and acquisition rumors by big pharma.
The key driver was positive data from VK2735, Viking's obesity drug candidate. In the Phase 2 VENTURE study, participants achieved an average 14.7% weight reduction.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
This positions VK2735 as a strong rival in the obesity treatment market, dominated by GLP-1 therapies like Ozempic and Wegovy.
Original source: Ad Hoc News
View original article →Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.
Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.
